The first patient has been dosed in a phase 2 clinical trial investigating SURF-100 for the treatment of chronic dry eye disease, according to a press release from Surface Ophthalmics.
The head-to-head study is evaluating SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) against Xiidra (lifitegrast ophthalmic solution 5%, Novartis) and Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan).
The study aims to enroll about 300 patients. The primary endpoint is statistically significant symptom improvement between the study arms on the University of North
Uncategorized